Vascular Dementia Clinical Trial
Official title:
A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel, Comparative, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)
Verified date | November 2011 |
Source | Sinphar Pharmaceutical Co., Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Food and Drug Administration |
Study type | Interventional |
The objectives of this phase II study of STA-1 capsule was to make preliminary evaluation on clinical efficacy and safety of STA-1 capsule in order that based on the dosage and study structure planned in this project, the dosage and study structure of phase III study can be confirmed.
Status | Completed |
Enrollment | 240 |
Est. completion date | October 2002 |
Est. primary completion date | October 2002 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 45 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Meeting criteria of dementia according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) 2. Meeting criteria of vascular dementia according to National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS/AIREN) 3. With Mini-Mental State Examination (MMSE score) ?17 (illiteracy); ?20 (elementary school); ?24 (high school or above) 4. With Hachinski's ischemic score (HIS) ?7 5. With marrow-sea deficiency from Chinese medicine's perspective 6. Classified mild to moderate dementia based on MMSE score 7. With body weight 45 to 95 Kg 8. Aged 45 to 80 years old (inclusive). Either gender is eligible. Female subjects must be postmenopausal (for at least 1 year) women without fertility 9. Having signed informed consent form 10. Correct understanding of pharmaceutical research and good compliance to study personnel's observation and evaluation Exclusion Criteria: 1. Dementia besides study indication based on DSM-IV and NINDS/AIREN, e.g. Alzheimer's disease, Lwey body disease, etc. 2. With HIS < 7 3. Diagnosed significant depression based on DSM-IV with score >8 or with other mental diseases/disorders 4. With cognitive dysfunction caused by head impairment 5. With medical history of epilepsy, encephalitis, or any other diseases that may result in dementia, e.g. Parkinson's disease, Huntington disease, Pick disease, etc. Patients with epilepsy attacked occasionally should be examined at the first visit by electroencephalography (EEG) and should be excluded from this study if by the test results are positive. 6. With certain diseases that may interfere the evaluation of cognitive function, including abuse of alcohol, or DSM-IV diagnosed abuse of drugs or mental drugs in past 5 years. Severe anemia patients should also be excluded. 7. With severe mental dysfunction, e.g. hemiplegia, aphasia, visually and hearing impairment, etc. 8. With cardiac disorder, e.g. heart rate ? 50 or ? 180 times/minute 9. With supine or sitting Systolic blood pressure ? 100 or ? 180 mmHg 10. With other disease, especially hepatic, renal, or cardiac disorders, e.g. ALT/SGPT or AST/SGOT > 3 times of upper limit of normal range, serum creatinine > 177 umol/L (2mg/dL), or congestive heart failure (cardiac function 2-4 in classification) 11. With malignant neoplasm 12. With thyroid dysfunction or syphilis 13. Failed to control diabetes. Diabetes patients can not enter the study unless the status becomes stable through dietary modification, taking hypoglycemic agents, or receiving insulin. 14. With asthma or chronic obstructive pulmonary disease 15. With multiple neuritis 16. With myasthenia gravis and amyotrophic 17. With severe indigestion, or gastrointestinal obstruction, or gastric and duodenal ulcer, or other gastrointestinal diseases that can affect drug absorption 18. With glaucoma 19. Ever attending other clinical trials in past 30 days |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Affiliated Hospital of Chengdu University of Traditional Chinese Medicines, China | Chengdu | |
China | Fujian Academy of Traditional Chinese Medicine | Fujian | |
China | Hospital (Traditional Chinese Medicine) Affiliated to Luzhou Medical College | Luzhou | |
China | Affiliated Hospital of Shaanxi Academy of Traditional Chinese Medicine, | Shaanxi | |
China | Xi'an Traditional Chinese Medicine Hospital | Xi'an |
Lead Sponsor | Collaborator |
---|---|
Sinphar Pharmaceutical Co., Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes from Baseline in Mini-Mental State Examination (MMSE) | MMSE were used to evaluate subject's change in orientation, attention and calculation, immediate recall and delayed memory, and language ability before and after treatment. | Month 1, Month 2, , Month 3, , Month 6 | No |
Primary | Changes from Baseline in Blessed-Roth Behavior Scale (BBS) | Month 1, Month 2, , Month 3, , Month 6 | No | |
Primary | Changes from Baseline in Activities of Daily Living (ADL) | Month 1, Month 2, , Month 3, , Month 6 | No | |
Secondary | Changes from Baseline in the symptom scales from Chinese medicine's perspective | Month 1, Month 2, , Month 3, , Month 6 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT04109963 -
Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment
|
Phase 2 | |
Recruiting |
NCT04335994 -
ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
|
N/A | |
Not yet recruiting |
NCT06416371 -
Retinal Vessel Leakage in Cerebral Small Vessel Disease
|
||
Completed |
NCT01761227 -
Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia
|
Phase 2 | |
Active, not recruiting |
NCT01208675 -
The Swedish BioFINDER Study
|
||
Completed |
NCT00165763 -
Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia
|
Phase 4 | |
Completed |
NCT00621647 -
Seroquel- Agitation Associated With Dementia
|
Phase 3 | |
Recruiting |
NCT04095962 -
Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia
|
N/A | |
Recruiting |
NCT03275363 -
The University of Hong Kong Neurocognitive Disorder Cohort
|
N/A | |
Active, not recruiting |
NCT03804229 -
Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia
|
Phase 3 | |
Enrolling by invitation |
NCT03724136 -
Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study
|
N/A | |
Completed |
NCT02453932 -
Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia
|
Phase 3 | |
Completed |
NCT00947531 -
A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia
|
Phase 4 | |
Not yet recruiting |
NCT03702543 -
Managing Vascular Dementia Risk Factors With SymTrend
|
Phase 1 | |
Enrolling by invitation |
NCT02147652 -
Personalized Music Therapy and Agitation in Dementia
|
N/A | |
Recruiting |
NCT04114994 -
Longitudinal Cognitive Assessment by BoCA
|
||
Recruiting |
NCT06034509 -
Cognitive and Vascular Functioning Following TBI
|
||
Recruiting |
NCT05921266 -
Urolithin A Supplementation in Middle-aged Adults With Obesity
|
N/A | |
Not yet recruiting |
NCT01466543 -
Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity
|
Phase 2 |